AC6.F ALZECURE PHARMA AB
- Market cap
- EUR 64.6M
- P/E
- 18.7x
- P/B
- 7.52x
- ROE
- 128.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is AC6.F undervalued?
Graham numberAC6.F trades 150.3% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
ALZECURE PHARMA AB fundamental analysis
No fundamental analysis for ALZECURE PHARMA AB yet.
ALZECURE PHARMA AB stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About ALZECURE PHARMA AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinso…
Full company profileALZECURE PHARMA AB financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
ALZECURE PHARMA AB annual financial statements (SEK; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 195M |
| Operating Income | -78.1M | -56.6M | -38.3M | -36.0M | -48.0M | 117M |
| EBITDA | - | -55.7M | -36.7M | -33.6M | -46.1M | 118M |
| Net Income | -77.8M | -56.2M | -37.2M | -35.3M | -47.7M | 117M |
| EPS | -1.67 | -0.81 | -0.44 | -0.38 | -0.36 | 1.02 |
| Balance Sheet | ||||||
| Total Assets | 45.6M | 70.8M | 37.8M | 34.4M | 59.0M | 122M |
| Total Liabilities | 12.7M | 10.4M | 14.1M | 8.25M | 26.1M | 31.0M |
| Shareholders' Equity | 33.0M | 60.5M | 23.8M | 26.2M | 32.9M | 91.4M |
| Cash & Short-term Investments | 41.7M | 25.6M | 29.1M | 31.5M | 50.3M | 13.5M |
| Cash Flow | ||||||
| Operating Cash Flow | -70.6M | -99.9M | 3.06M | -34.2M | -34.6M | -72.6M |
| Capital Expenditure | 54.0K | 0.00 | 0.00 | 124K | 0.00 | 0.00 |
| Free Cash Flow | -70.7M | -99.9M | 3.06M | -34.4M | -34.6M | -72.6M |
| Ratios | ||||||
| ROE | -235.9% | -93.0% | -156.3% | -135.0% | -144.8% | 128.0% |
| ROA | -170.4% | -79.4% | -98.2% | -102.7% | -80.7% | 95.6% |
| Net Profit Margin | - | - | - | - | - | 60.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
ALZECURE PHARMA AB dividends
ALZECURE PHARMA AB has not paid dividends in the last 5 fiscal years.
Who owns ALZECURE PHARMA AB
- Insiders 32.99%
- Institutions 10.57%
- Public & others 56.45%
- Shares outstanding 115M
- Free float 92.1M
ALZECURE PHARMA AB company profile
- Company name
- ALZECURE PHARMA AB
- Ticker
- AC6.F
- ISIN
- SE0010133785
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 10
- Fiscal year end
- December
- Address
- Hälsovägen 7, Huddinge, Sweden, 141 57
- Phone
- 46 7 63 16 24 77
- Website
- alzecurepharma.se
About ALZECURE PHARMA AB
AlzeCure Pharma AB (publ) operates as a pharmaceutical company that develops small-molecule drug therapies for the treatment of severe diseases and conditions that affect the central nervous system. The company is involved in the development of drug candidates based on the NeuroRestore, Alzstatin, and Painless research platforms. Its products pipeline includes ACD856 for the treatment of Alzheimer's disease, sleep disorders, depression, traumatic brain injuries, and Parkinson's disease, which is in phase I clinical trial; ACD857 and ACD680 that are in preclinical trial for the treatment of Alzheimer's disease; ACD440, a TRPV1 antagonist, which is in phase II clinical trial for neuropathic pain indications; and ACD137 negative allosteric modulator (NAM) of TrkA receptors for osteoarthritic pain indications, which is in preclinical phase. AlzeCure Pharma AB (publ) was founded in 2012 and is based in Huddinge, Sweden.
ALZECURE PHARMA AB management
4- Dr. Johan SandinChief Scientific Officer & Interim CEO · born 1970
- Ms. Birgitta LundvikChief Financial Officer · born 1967
- Dr. Marta Segerdahl Storck M.D., Ph.D.Chief Medical Officer · born 1956
- Dr. Cecilia Wadell MSc Pharm, Ph.D.Head of Development